A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects

Phase 1 Completed 24 enrolled Pfizer

RandomizedParallel-groupDouble-blindBasic science

Summary

PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after 2 weeks of dosing of PF-06427878 in overweight-obese, otherwise healthy adult subjects.

Timeline

Start: 2016-08-24
Primary completion: 2017-04-12
Completion: 2017-04-12

Publications

Amin NB, Carvajal-Gonzalez S, Purkal J, Zhu T, Crowley C, Perez S, Chidsey K, Kim AM, Goodwin B. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. Sci Transl Med. 2019 Nov 27;11(520):eaav9701. doi: 10.1126/scitranslmed.aav9701.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-06427878	Small molecule	500 mg	Oral

Indications

No indication recorded.